Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$0.93
+0.1%
$0.97
$0.61
$20.44
$14.01M-0.141.10 million shs180,432 shs
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
$1.37
$1.21
$0.78
$2.55
$19.67M0.55211,100 shs23,221 shs
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
$0.00
$0.00
$0.15
$4.96M1.5312,042 shsN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
$0.49
+2.3%
$0.59
$0.47
$2.37
$16.05M0.0276,338 shs19,845 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-2.33%-14.08%-13.28%+14.27%-94.62%
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
-2.14%-0.72%+2.24%-15.43%+50.75%
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
0.00%0.00%0.00%0.00%-99.80%
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-10.13%-6.43%-20.41%-34.69%-69.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.535 of 5 stars
0.04.00.00.01.60.00.6
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
3.7714 of 5 stars
3.55.00.00.04.11.71.3
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
N/AN/AN/AN/AN/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
3.1527 of 5 stars
3.55.00.00.03.60.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00
N/AN/AN/A
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$8.50520.44% Upside
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
0.00
N/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
3.00
Buy$4.50829.75% Upside

Current Analyst Ratings Breakdown

Latest IPCIF, PMN, ALLR, and CMMB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00
5/12/2025
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
4/1/2025
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A($559.39) per shareN/A
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$1.54 per shareN/A
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
$660K0.00N/AN/A($0.32) per share0.00
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$11.90MN/A0.00N/AN/AN/A-369.67%-100.06%8/4/2025 (Estimated)
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
-$24.22M-$0.76N/AN/AN/AN/A-101.70%-76.18%N/A
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
-$2.89M-$0.16N/AN/AN/AN/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-$13.21M-$0.05N/AN/AN/AN/A-636.20%-130.32%8/14/2025 (Estimated)

Latest IPCIF, PMN, ALLR, and CMMB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
-$0.20-$0.14+$0.06-$0.14N/AN/A
5/13/2025Q1 2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$8.10-$0.25+$7.85-$0.25N/AN/A
5/12/2025Q1 2025
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-$0.14-$0.21-$0.07-$0.21N/AN/A
3/31/2025Q4 2024
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-$0.14-$0.02+$0.12-$0.02N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
N/AN/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.75
2.75
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
N/A
4.57
4.57
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
N/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/A
9.30
9.30
CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
1015.08 million4.43 millionNot Optionable
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
2014.36 million12.65 millionNot Optionable
Intellipharmaceutics International Inc. stock logo
IPCIF
Intellipharmaceutics International
1033.09 million32.51 millionNot Optionable
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
532.69 million31.25 millionNot Optionable

Recent News About These Companies

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial
ProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$0.93 +0.00 (+0.12%)
As of 01:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$1.37 0.00 (0.00%)
As of 12:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Intellipharmaceutics International stock logo

Intellipharmaceutics International OTCMKTS:IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

ProMIS Neurosciences stock logo

ProMIS Neurosciences NASDAQ:PMN

$0.49 +0.01 (+2.29%)
As of 12:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.